528 related articles for article (PubMed ID: 12605647)
21. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study.
Ordóñez NG
Mod Pathol; 2006 Mar; 19(3):417-28. PubMed ID: 16415794
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.
Abutaily AS; Addis BJ; Roche WR
J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995
[TBL] [Abstract][Full Text] [Related]
23. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura.
Miettinen M; Sarlomo-Rikala M
Am J Surg Pathol; 2003 Feb; 27(2):150-8. PubMed ID: 12548160
[TBL] [Abstract][Full Text] [Related]
24. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983
[TBL] [Abstract][Full Text] [Related]
25. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.
Klebe S; Swalling A; Jonavicius L; Henderson DW
J Clin Pathol; 2016 Feb; 69(2):136-41. PubMed ID: 26281863
[TBL] [Abstract][Full Text] [Related]
26. A cytokeratin- and calretinin-negative staining sarcomatoid malignant mesothelioma.
Hurtuk MG; Carbone M
Anticancer Res; 2004; 24(5B):3097-102. PubMed ID: 15510595
[TBL] [Abstract][Full Text] [Related]
27. The value of 'mesothelium-associated' antibodies in distinguishing between metastatic renal cell carcinomas and mesotheliomas.
Osborn M; Pelling N; Walker MM; Fisher C; Nicholson AG
Histopathology; 2002 Oct; 41(4):301-7. PubMed ID: 12383211
[TBL] [Abstract][Full Text] [Related]
28. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
Ordóñez NG
Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
[TBL] [Abstract][Full Text] [Related]
29. Expression of muscle actins in diffuse mesotheliomas.
Kung IT; Thallas V; Spencer EJ; Wilson SM
Hum Pathol; 1995 May; 26(5):565-70. PubMed ID: 7538485
[TBL] [Abstract][Full Text] [Related]
30. Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases.
Knuuttila A; Jee KJ; Taskinen E; Wolff H; Knuutila S; Anttila S
Virchows Arch; 2006 Feb; 448(2):135-41. PubMed ID: 16170537
[TBL] [Abstract][Full Text] [Related]
31. Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy.
Lee M; Alexander HR; Burke A
Pathology; 2013 Aug; 45(5):464-73. PubMed ID: 23846294
[TBL] [Abstract][Full Text] [Related]
32. Malignant epithelioid mesothelioma: anti-mesothelial marker expression correlates with histological pattern.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2001 Dec; 39(6):584-8. PubMed ID: 11903576
[TBL] [Abstract][Full Text] [Related]
33. Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
Capkova L; Koubkova L; Kodet R
Neoplasma; 2014; 61(2):161-9. PubMed ID: 24471939
[TBL] [Abstract][Full Text] [Related]
34. Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions.
Derakhshan F; Ionescu D; Cheung S; Churg A
Arch Pathol Lab Med; 2020 Feb; 144(2):185-188. PubMed ID: 31484000
[TBL] [Abstract][Full Text] [Related]
35. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
36. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura.
Cury PM; Butcher DN; Fisher C; Corrin B; Nicholson AG
Mod Pathol; 2000 Feb; 13(2):107-12. PubMed ID: 10697265
[TBL] [Abstract][Full Text] [Related]
37. GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.
Piao ZH; Zhou XC; Chen JY
Virchows Arch; 2021 Aug; 479(2):257-263. PubMed ID: 33570661
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity.
Yaziji H; Battifora H; Barry TS; Hwang HC; Bacchi CE; McIntosh MW; Kussick SJ; Gown AM
Mod Pathol; 2006 Apr; 19(4):514-23. PubMed ID: 16554731
[TBL] [Abstract][Full Text] [Related]
39. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
40. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review.
Klebe S; Mahar A; Henderson DW; Roggli VL
Mod Pathol; 2008 Sep; 21(9):1084-94. PubMed ID: 18587319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]